- Academic-Industry Partnerships
- Cardiovascular Disease
- Strategic Project Development
- Drug Discovery
Previous Positions/ Qualifications
- OxStem, Oxford University 2018-current
- Prince2 Practitioner 2018
- Duke-NUS Medical School Singapore, Research Fellow and Titin Project Manager 2015-2016
- Imperial College London, MAP4K4 Biology Drug Discovery Team Lead 2010-2014
- University College London, Postdoctoral Research Associate 2009-2010
- Cardiff University, Postdoctoral Research Associate 2007-2008
- PhD, Cardiff University College of Medicine 2003-2007
- Adprotech, Great Chesterford Research Park, Cambridge 2001-2003
Visiting Scientist Positions
- Centre for Organismal Studies, Heidelberg University, Germany - 2019
- Cancer Research UK Cambridge Research Institute, Cambridge - 2009
- Institute of Pathobiochemistry, Muenster University, Germany - 2007
Lorna R. Fiedler
Visiting Postdoctoral Scientist in Cardiac Regenerative Biology
In August 2017 I joined OxStem Cardio, a spin-out from Oxford University headed by Professors Paul Riley and Roger Patient. Our goal is to find novel drugs to regenerate the damaged heart by applying phenotype based approaches. My role is in supporting strategic project development and using teleost fish systems for effiacy studies, validation and for exploring underlying injury response mechanisms.
I transitioned from the biotechnology sector developing complement based therapeutics to studying cardiovascular disease in academia. Latterly, I was biology team lead at Imperial College with Professor Michael Schneider, where we developed novel drugs that are cardioprotective in mouse models of heart attack (Fiedler et al., 2019, Cell Stem Cell). Prior to joining OxStem I held a research fellow position at Duke-NUS Singapore, project managing and conducting studies on the genetic basis of cardiac disease.
My academic interest is in understanding the molecular mechanisms of life and death in the heart to identify new therapies. I also aim to improve clinical translation by developing and incorporating more relevant pre-clinical models into drug discovery workflows.
In addition, I have an interest creating and promoting a healthy and supportive working environment. At Oxford University, I am a Harassment Advisor and member of the Environment and Culture working group. I am also a founding member of the RDM Researchers Association and on the Self-Assessment Team for Athena Swan. My current focus is to introduce mental health first aid (MHFA) training within the department and to work closely with others to promote the role of the harassment advisors in maintaining a happy and healthy working environment.
MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo.
Fiedler LR. et al, (2019), Cell Stem Cell, 24, 579 - 591.e12
Titin truncations lead to impaired cardiomyocyte autophagy and mitochondrial function in vivo
Zhou J. et al, (2019), Human Molecular Genetics
Inhibiting the Inhibitors, PTP1B as a Therapeutic Target in Myocardial Infarction
Fiedler LR., (2018), Heart Research - Open Journal, 5, 8 - 11
Titin-truncating variants affect heart function in disease cohorts and the general population
Schafer S. et al, (2016), Nature Genetics, 49, 46 - 53
VEGF Signaling: Methods and Protocols. Preface.
Fiedler L., (2015), Methods Mol Biol, 1332, v - vi